Cargando…

Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study

IMPORTANCE: Persistently depressed left ventricular ejection fraction (LVEF) after myocardial infarction (MI) is associated with adverse prognosis and directs the use of evidence-based treatments to prevent sudden cardiac death and/or progressive heart failure. OBJECTIVE: To assess adherence with gu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilton, Stephen B., Bennett, Matthew T., Parkash, Ratika, Kavanagh, Katherine, Jolicoeur, E. Marc, Halperin, Frank, Jolly, Umjeet, Leong-Sit, Peter, Sas, Rozsa, Chew, Derek S., Singh, Sarah, Frisbee, Stephanie, MacLachlan, Robert, Manlucu, Jaimie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640891/
https://www.ncbi.nlm.nih.gov/pubmed/34854904
http://dx.doi.org/10.1001/jamanetworkopen.2021.36830
_version_ 1784609403179106304
author Wilton, Stephen B.
Bennett, Matthew T.
Parkash, Ratika
Kavanagh, Katherine
Jolicoeur, E. Marc
Halperin, Frank
Jolly, Umjeet
Leong-Sit, Peter
Sas, Rozsa
Chew, Derek S.
Singh, Sarah
Frisbee, Stephanie
MacLachlan, Robert
Manlucu, Jaimie
author_facet Wilton, Stephen B.
Bennett, Matthew T.
Parkash, Ratika
Kavanagh, Katherine
Jolicoeur, E. Marc
Halperin, Frank
Jolly, Umjeet
Leong-Sit, Peter
Sas, Rozsa
Chew, Derek S.
Singh, Sarah
Frisbee, Stephanie
MacLachlan, Robert
Manlucu, Jaimie
author_sort Wilton, Stephen B.
collection PubMed
description IMPORTANCE: Persistently depressed left ventricular ejection fraction (LVEF) after myocardial infarction (MI) is associated with adverse prognosis and directs the use of evidence-based treatments to prevent sudden cardiac death and/or progressive heart failure. OBJECTIVE: To assess adherence with guideline-recommended LVEF reassessment and to study the evolution of LVEF over 6 months of follow-up. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter cohort study at Canadian academic and community hospitals with on-site cardiac catheterization services. Patients with type 1 acute MI and LVEF less than or equal to 45% during the index hospitalization were enrolled between January 2018 and August 2019 and were followed-up for 6 months. Data analysis was performed from May 2020 to September 2021. EXPOSURES: Baseline clinical factors, in-hospital care and LVEF, and site-specific features. MAIN OUTCOMES AND MEASURES: The main outcomes were receipt of repeat LVEF assessment by 6 months and the presence of a persistent LVEF reduction at 2 thresholds: LVEF less than or equal to 40%, prompting consideration of additional medical therapy for heart failure, or LVEF less than or equal to 35%, prompting referral for implanted cardioverter defibrillator in addition to medical therapy. RESULTS: This study included 501 patients (mean [SD] age, 63.3 [13.0] years; 113 women [22.6%]). Overall, 370 patients (73.4%) presented with STEMI, and 454 (90.6%) had in-hospital revascularization. The median (IQR) baseline LVEF was 40% (34%-43%). Of 458 patients (91.4%) who completed the 6-month follow-up, 303 (66.2%; 95% CI, 61.7%-70.5%) had LVEF reassessment, with a range of 46.7% to 90.0% across sites (χ(2)(13) = 19.6; P = .11). Participants from community hospitals were more likely than those from academic hospitals to undergo LVEF reassessment (73.6% vs 63.2%; χ(2)(1) = 4.50; P = .03), as were those with worse LVEF at baseline. Follow-up LVEF improved by an absolute median (IQR) of 8% (3%-15%). However, 103 patients (34.1%) met the definitions of clinically relevant LVEF reduction, including 52 patients (17.2%) with LVEF less than or equal to 35% and 51 patients (16.9%) with LVEF of 35.1% to 40.0%. CONCLUSIONS AND RELEVANCE: In this cohort study, approximately 1 in 3 patients with at least mild LVEF reduction after acute MI did not undergo indicated LVEF reassessment within 6 months, suggesting that programs to improve the quality of post-MI care should include measures to ensure that indicated repeat cardiac imaging is performed. In those with follow-up imaging, clinically relevant persistent LVEF reduction was identified in more than one-third of patients.
format Online
Article
Text
id pubmed-8640891
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-86408912021-12-08 Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study Wilton, Stephen B. Bennett, Matthew T. Parkash, Ratika Kavanagh, Katherine Jolicoeur, E. Marc Halperin, Frank Jolly, Umjeet Leong-Sit, Peter Sas, Rozsa Chew, Derek S. Singh, Sarah Frisbee, Stephanie MacLachlan, Robert Manlucu, Jaimie JAMA Netw Open Original Investigation IMPORTANCE: Persistently depressed left ventricular ejection fraction (LVEF) after myocardial infarction (MI) is associated with adverse prognosis and directs the use of evidence-based treatments to prevent sudden cardiac death and/or progressive heart failure. OBJECTIVE: To assess adherence with guideline-recommended LVEF reassessment and to study the evolution of LVEF over 6 months of follow-up. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter cohort study at Canadian academic and community hospitals with on-site cardiac catheterization services. Patients with type 1 acute MI and LVEF less than or equal to 45% during the index hospitalization were enrolled between January 2018 and August 2019 and were followed-up for 6 months. Data analysis was performed from May 2020 to September 2021. EXPOSURES: Baseline clinical factors, in-hospital care and LVEF, and site-specific features. MAIN OUTCOMES AND MEASURES: The main outcomes were receipt of repeat LVEF assessment by 6 months and the presence of a persistent LVEF reduction at 2 thresholds: LVEF less than or equal to 40%, prompting consideration of additional medical therapy for heart failure, or LVEF less than or equal to 35%, prompting referral for implanted cardioverter defibrillator in addition to medical therapy. RESULTS: This study included 501 patients (mean [SD] age, 63.3 [13.0] years; 113 women [22.6%]). Overall, 370 patients (73.4%) presented with STEMI, and 454 (90.6%) had in-hospital revascularization. The median (IQR) baseline LVEF was 40% (34%-43%). Of 458 patients (91.4%) who completed the 6-month follow-up, 303 (66.2%; 95% CI, 61.7%-70.5%) had LVEF reassessment, with a range of 46.7% to 90.0% across sites (χ(2)(13) = 19.6; P = .11). Participants from community hospitals were more likely than those from academic hospitals to undergo LVEF reassessment (73.6% vs 63.2%; χ(2)(1) = 4.50; P = .03), as were those with worse LVEF at baseline. Follow-up LVEF improved by an absolute median (IQR) of 8% (3%-15%). However, 103 patients (34.1%) met the definitions of clinically relevant LVEF reduction, including 52 patients (17.2%) with LVEF less than or equal to 35% and 51 patients (16.9%) with LVEF of 35.1% to 40.0%. CONCLUSIONS AND RELEVANCE: In this cohort study, approximately 1 in 3 patients with at least mild LVEF reduction after acute MI did not undergo indicated LVEF reassessment within 6 months, suggesting that programs to improve the quality of post-MI care should include measures to ensure that indicated repeat cardiac imaging is performed. In those with follow-up imaging, clinically relevant persistent LVEF reduction was identified in more than one-third of patients. American Medical Association 2021-12-02 /pmc/articles/PMC8640891/ /pubmed/34854904 http://dx.doi.org/10.1001/jamanetworkopen.2021.36830 Text en Copyright 2021 Wilton SB et al. JAMA Network Open. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License.
spellingShingle Original Investigation
Wilton, Stephen B.
Bennett, Matthew T.
Parkash, Ratika
Kavanagh, Katherine
Jolicoeur, E. Marc
Halperin, Frank
Jolly, Umjeet
Leong-Sit, Peter
Sas, Rozsa
Chew, Derek S.
Singh, Sarah
Frisbee, Stephanie
MacLachlan, Robert
Manlucu, Jaimie
Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
title Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
title_full Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
title_fullStr Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
title_full_unstemmed Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
title_short Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
title_sort variability in reassessment of left ventricular ejection fraction after myocardial infarction in the acute myocardial infarction quality assurance canada study
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640891/
https://www.ncbi.nlm.nih.gov/pubmed/34854904
http://dx.doi.org/10.1001/jamanetworkopen.2021.36830
work_keys_str_mv AT wiltonstephenb variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT bennettmatthewt variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT parkashratika variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT kavanaghkatherine variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT jolicoeuremarc variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT halperinfrank variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT jollyumjeet variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT leongsitpeter variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT sasrozsa variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT chewdereks variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT singhsarah variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT frisbeestephanie variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT maclachlanrobert variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy
AT manlucujaimie variabilityinreassessmentofleftventricularejectionfractionaftermyocardialinfarctionintheacutemyocardialinfarctionqualityassurancecanadastudy